Skip to content
PubMed This is a summary of 7 peer-reviewed journal articles Updated
Endocrinology · Hereditary Hypophosphatemic Rickets with Hypercalciuria

The Standard of Care: Treating HHRH with Precision

At a Glance

HHRH treatment centers on individualized oral phosphate, which replaces kidney phosphate losses and may lower excess active vitamin D and urinary calcium. Active vitamin D medicines are generally avoided, and regular blood and urine monitoring helps reduce risks from kidney stones and calcification.

Treating Hereditary Hypophosphatemic Rickets with Hypercalciuria (HHRH) requires a specialized approach. Because the underlying problem is a specific kidney “leak,” the treatment must be precisely targeted to compensate for that leak without causing additional harm to your kidneys [1][2].

The Core Treatment: Oral Phosphate

The primary treatment for significant phosphate wasting in HHRH and NPHLOP1 is oral phosphate supplementation [1][2].

  • The Goal: By taking phosphate by mouth, you replace what your kidneys are losing. This raises your blood phosphate levels and sends a signal to your body to stop overproducing active vitamin D [3][4].
  • The Result: When active vitamin D levels drop, your gut stops absorbing excessive calcium, which can help reduce the amount of calcium that ends up in your urine (hypercalciuria) [3].
  • Individualized Therapy: Phosphate dosing requires precise, individualized tuning. Excessive phosphate can cause gastrointestinal side effects (like diarrhea) and may contribute to secondary hyperparathyroidism. Furthermore, while it often corrects blood phosphate, it may not completely resolve kidney calcifications or stone risk for everyone [4][2].

Medication Safety: Active Vitamin D

In many types of rickets (like XLH), doctors routinely prescribe active vitamin D (calcitriol or alfacalcidol). In confirmed HHRH, this is generally contraindicated and should be avoided [1][5].

  • Why it’s avoided: Your body is already naturally overproducing active vitamin D. Adding more can increase your intestinal calcium absorption, leading to dangerously high levels of calcium in your urine. This can worsen kidney stones and nephrocalcinosis [1][3].
  • Nutritional D vs. Active D: It is vital to distinguish between active vitamin D (the medication you should generally avoid) and nutritional vitamin D (25-hydroxyvitamin D). You still require a normal amount of nutritional vitamin D for general health. If you are deficient in 25-hydroxyvitamin D, your doctor may still prescribe careful supplementation [2].
  • Important Warning: Never start, stop, or change your phosphate, vitamin D, or calcium supplements without explicit instructions from your prescribing clinician.

Adjunctive Treatments for Kidney Protection

If your urine calcium remains high or you continue forming stones even after starting phosphate therapy, your specialist may add other treatments based on your 24-hour urine chemistry and stone composition:

  • Thiazide Diuretics: Medications like hydrochlorothiazide or chlorthalidone may be used in selected cases to help the kidneys reabsorb calcium, reducing the amount that spills into the urine [6][3].
  • Potassium Citrate: This may be prescribed to alter urine chemistry and prevent stones, provided your kidney function and potassium levels safely allow it [7].
  • Dietary Adjustments: Patients with calcium stones are generally advised not to severely restrict normal dietary calcium, as this can worsen bone health. However, salt (sodium) restriction may be recommended to help lower urinary calcium excretion [7].
  • Hydration: Maintaining an individualized fluid intake is critical to dilute the urine and prevent stone crystallization.

Managing HHRH is a marathon, not a sprint. It requires frequent, individualized dosing because phosphate leaves your system quickly [7]. You will need ongoing clinician-directed blood and urine tests to ensure your phosphate is balanced and your kidneys are protected [2][3].

Common questions in this guide

What is the main treatment for HHRH?
The main treatment for significant phosphate wasting in HHRH is individualized oral phosphate supplementation. It replaces phosphate lost in the urine and may lower excess active vitamin D and urinary calcium, but blood and urine tests are needed to adjust the dose safely.
Why are calcitriol and alfacalcidol usually avoided in HHRH?
HHRH already causes the body to make too much active vitamin D. Adding calcitriol or alfacalcidol can increase calcium absorption, raise urine calcium, and worsen kidney stones or calcium buildup in the kidneys.
Can I take regular vitamin D if I have HHRH?
Nutritional vitamin D, measured as 25-hydroxyvitamin D, is different from active vitamin D medicines. If your nutritional vitamin D is low, a clinician may recommend careful supplementation, but you should not start or change it without medical guidance.
What can help if phosphate does not control my high urine calcium?
If hypercalciuria or kidney stones persist, a specialist may consider a thiazide diuretic or potassium citrate. The choice depends on 24-hour urine results, kidney function, potassium levels, and the type of stone.
Should I restrict calcium in my diet to prevent HHRH kidney stones?
Severely restricting normal dietary calcium is generally not advised because it can worsen bone health. Your clinician may instead recommend maintaining a normal calcium intake, limiting sodium, and drinking an individualized amount of fluid.
What side effects can oral phosphate cause?
Oral phosphate can cause stomach upset or diarrhea, and excessive dosing may contribute to secondary hyperparathyroidism. Tell your prescribing clinician about side effects rather than changing the dose yourself.

Get notified when new evidence is published on nephrolithiasis/osteoporosis, hypophosphatemic.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (7)
  1. 1

    Hereditary hypophosphatemic rickets with hypercalciuria: pathophysiology, clinical presentation, diagnosis and therapy.

    Bergwitz C, Miyamoto KI

    Pflugers Archiv : European journal of physiology 2019; (471(1)):149-163 doi:10.1007/s00424-018-2184-2.

    PMID: 30109410
  2. 2

    Rickets guidance: part II-management.

    Haffner D, Leifheit-Nestler M, Grund A, Schnabel D

    Pediatric nephrology (Berlin, Germany) 2022; (37(10)):2289-2302 doi:10.1007/s00467-022-05505-5.

    PMID: 35352187
  3. 3

    Phosphate matters when investigating hypercalcemia: a mutation in SLC34A3 causing HHRH

    Tang AR, Hinz LE, Khan A, Kline GA

    Endocrinology, diabetes & metabolism case reports 2019; (2019(1)):1-6 doi:10.1530/EDM-19-0058.

    PMID: 31352694
  4. 4

    An update on clinical presentation and responses to therapy of patients with hereditary hypophosphatemic rickets with hypercalciuria (HHRH).

    Zhu Z, Bo-Ran Ho B, Chen A, et al.

    Kidney international 2024; (105(5)):1058-1076 doi:10.1016/j.kint.2024.01.031.

    PMID: 38364990
  5. 5

    Hereditary Hypophosphatemic Rickets with Hypercalciuria-Importance of Further Evaluation when Clinical Suspicion is Strong

    Wettasinghe CA, Kumarasiri IM, Vidushajini M, et al.

    Journal of clinical research in pediatric endocrinology 2026; (18(3)):549-553 doi:10.4274/jcrpe.galenos.2025.2025-1-15.

    PMID: 40820604
  6. 6

    Novel Variant of SLC34A3 in a Compound Heterozygous Brazilian Girl with Hereditary Hypophosphatemic Rickets with Hypercalciuria

    Valadares LP, de Carvalho DR

    Journal of clinical research in pediatric endocrinology 2025; (17(3)):326-331 doi:10.4274/jcrpe.galenos.2023.2023-5-2.

    PMID: 37680384
  7. 7

    Growth hormone therapy in HHRH.

    Filler G, Schott C, Salerno FR, et al.

    Bone reports 2022; (16()):101591 doi:10.1016/j.bonr.2022.101591.

    PMID: 35663378

This page is for informational purposes only and does not constitute medical advice about HHRH. Do not change phosphate, vitamin D, calcium, or kidney-stone treatment without guidance from your prescribing clinician.